Endemic Gallbladder Cancer: Is There a Role for Prophylactic Cholecystectomy?

Elan R. Witkowski
University of Massachusetts Medical School

Let us know how access to this document benefits you.
Follow this and additional works at: https://escholarship.umassmed.edu/cts_retreat

Part of the Neoplasms Commons, and the Surgery Commons

Repository Citation

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License. This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
ENDEMIC GALLBLADDER CANCER: IS THERE A ROLE FOR PROPHYLACTIC CHOLECYSTECTOMY?

Elan R. Witkowski MD, Elizaveta Ragulin-Coyne MD MHS, Theodore P. McDade MD, Lily W. Chen BS, Heena P. Santry MD MS, Shimul A. Shah MD, Jennifer F. Tseng MD MPH

Department of Surgery, Surgical Outcomes Analysis & Research (SOAR), University of Massachusetts Medical School, Worcester MA

Contact Information: Elan.Witkowski@umassmemorial.org

Background: Gallbladder cancer (GBC) is an often lethal malignancy with variable distribution. Incidence in the United States is low. However, in areas of Central/South America, Central Europe, Japan, and the Indian subcontinent, GBC is a major cause of cancer death. Cholecystectomy is safe and commonly performed worldwide. Thus, prophylactic cholecystectomy (PCCY) has been proposed in regions with endemic GBC. We developed a simple decision model to assist caregivers in determining the optimal strategy for managing GBC based on local incidence and technological capabilities.

Methods: Rates of disease and outcomes were derived from a review of the literature. Using TreeAge-Pro software, a decision model was created to simulate expected health outcomes for populations with high GBC incidence, following 3 treatment strategies: no early intervention, one-time screening ultrasound (US), or PCCY. Lifetime cancer-specific survival was the outcome of interest. Sensitivity analyses were performed to determine threshold values.

Results: Based on our model, populations where lifetime risk of GBC exceeds 0.4% may benefit from early intervention by US or PCCY. Two-way sensitivity analysis shows that over a relatively narrow range of disease incidence, US may be favored if sensitivity exceeds 50%. In many cases where lifetime risk exceeds 1%, PCCY may improve survival.

Conclusions: GBC varies in incidence, but affects many individuals in some populations in the Americas. The lethality of GBC may justify aggressive public health intervention including screening or prophylactic cholecystectomy. Decision analysis models using best-available evidence may help determine the optimal treatment of individuals at risk for GBC.

Figure: Two-way sensitivity analysis demonstrating optimal strategies with varying risk of disease and ultrasound sensitivity.